Canada markets closed

Addex Therapeutics Ltd (ADDXF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.99000.0000 (0.00%)
At close: 10:31AM EDT
Full screen
Trade prices are not sourced from all markets
Previous Close0.9900
Open0.9900
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.9900 - 0.9900
52 Week Range0.9900 - 1.6500
Volume100
Avg. Volume0
Market Cap32.099M
Beta (5Y Monthly)1.32
PE Ratio (TTM)N/A
EPS (TTM)-0.5440
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est28.00
  • GlobeNewswire

    Addex Terminates Dipraglurant Phase 2b/3 Study in Patients with Dyskinesia Associated with Parkinson’s Disease due to Slow Recruitment Rate

    COVID-19 related challenges negatively impacted patient recruitment Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, June 17, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that it has terminated the Phase 2b/3 study evaluating dipraglurant as a potential treatment for dyskinesia associated with Parkinson’s disease (PD-LID) due to the slow recrui

  • GlobeNewswire

    Addex Provides Update on Dipraglurant Blepharospasm Phase 2 Feasibility Clinical Study

    Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, May 27, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that the outcome of a small Phase 2a feasibility study of dipraglurant in patients with blepharospasm was inconclusive and did not meet all of its objectives. Dipraglurant is a metabotropic glutamate receptor subtype 5 negative allosteric modul

  • GlobeNewswire

    Addex Announces Participation in the H.C. Wainwright Global Investment Conference

    Geneva, Switzerland, May 19, 2022 - Addex Therapeutics Ltd (SIX: ADXN, Nasdaq: ADXN), a clinical-stage pharmaceutical company pioneering allosteric modulation-based drug discovery and development, announced today that CEO, Tim Dyer, will be virtually attending the H.C. Wainwright Global Investment Conference taking place May 23 - 26, 2022. Mr. Dyer has also submitted a pre-recorded video presentation to the conference, in which he provides a corporate update and discusses recent developments at